November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Novo Nordisk Shares Slip as Drugmaker Highlights Bone Protection Data and Pediatric Weight Loss

💳 Personal Finance 2 min read 👁 2

Novo Nordisk shares fell 2.94% to $40.37 following new clinical data regarding its obesity treatments, including bone health biomarkers for CagriSema and pediatric BMI reductions.

Novo Nordisk Shares Slip as Drugmaker Highlights Bone Protection Data and Pediatric Weight Loss💳Personal Finance

Photo: Benzinga

Key points

  • Novo Nordisk shares fell 2.94% to $40.37 following new clinical presentations.
  • Preclinical and clinical findings showed amylin-based therapies help protect bone health during weight loss.
  • Phase 3 STEP Young trial results indicated a 17.4% mean BMI reduction in children using semaglutide.

Shares of Novo Nordisk declined 2.94% to trade at $40.37 following the presentation of new clinical data at ObesityWeek 2026. The updates covered the pharmaceutical company's pipeline for protecting bone integrity during substantial weight loss, alongside results from a pediatric obesity trial.

During weight reduction efforts, whether through medical treatments, surgical procedures, or dietary modifications, patients frequently experience a decline in bone mass and elevated fracture risks. To address this, the company highlighted findings showing that activating both amylin and calcitonin receptors helps preserve skeletal health. Preclinical trials demonstrated that treatments like cagrilintide and CagriSema limited trabecular bone deterioration compared to control groups, while phase 3 REDEFINE 1 trial data indicated that bone mineral density levels stayed within normal age and sex ranges despite notable weight loss.

Additionally, the company published primary outcomes from the phase 3 STEP Young study, evaluating once-weekly semaglutide injections in children aged six to under twelve with obesity. By week 68, children treated with semaglutide experienced an estimated mean body mass index reduction of 17.4%, compared to a 2.2% increase in the placebo group. The safety profile remained consistent with previous trials, according to the published data.

What to watch next: Investors should monitor upcoming regulatory milestones and longer-term follow-up studies regarding fracture risk reduction for the company's amylin pipeline.

Source Benzinga — benzinga.com/news/health-care/26/11/63342393/novo-nordisk-highlight… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.